Litcius/Paper detail

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccine-Breakthrough Infection Phenotype Includes Significant Symptoms, Live Virus Shedding, and Viral Genetic Diversity

Simon Pollett, Stephanie A Richard, Anthony C Fries, Mark P. Simons, Katrin Mende, Tahaniyat Lalani, Tida Lee, Sharon Chi, Rupal Mody, Cristian Madar, Anuradha Ganesan, Derek Larson, Christopher Colombo, Rhonda E Colombo, E Samuels, Christopher C. Broder, Eric D. Laing, Darci R. Smith, David R. Tribble, Brian K. Agan, Timothy Burgess

2021Clinical Infectious Diseases42 citationsDOIOpen Access PDF

Abstract

Little is known about severe acute respiratory syndrome coronavirus 2 "vaccine-breakthrough" infections (VBIs). Here we characterize 24 VBIs in predominantly young healthy persons. While none required hospitalization, a proportion endorsed severe symptoms and shed live virus as high as 4.13 × 103 plaque-forming units/mL. Infecting genotypes included both variant-of-concern (VOC) and non-VOC strains.

Topics & Concepts

VirologyMedicineViral sheddingSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirusCoronavirusCoronavirus disease 2019 (COVID-19)Attenuated vaccine2019-20 coronavirus outbreakRespiratory systemImmunologyBiologyOutbreakVirulenceGeneInternal medicineGeneticsInfectious disease (medical specialty)DiseaseSARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections StudiesViral gastroenteritis research and epidemiology
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccine-Breakthrough Infection Phenotype Includes Significant Symptoms, Live Virus Shedding, and Viral Genetic Diversity | Litcius